These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30796200)

  • 21. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.
    Lai Y; Zhao Z; Zeng T; Liang X; Chen D; Duan X; Zeng G; Wu W
    Cancer Cell Int; 2018; 18():31. PubMed ID: 29527128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of 3-bromopyruvate on the properties of cathepsin B in the aspect of metastatic potential of colon cancer cells.
    Szczuka I; Wiśniewski J; Kustrzeba-Wójcicka I; Terlecki G
    Adv Clin Exp Med; 2020 Aug; 29(8):949-957. PubMed ID: 32820873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
    Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
    Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and Clinical Implications of Cysteine Cathepsins in Gallbladder Carcinoma.
    Mehra S; Panwar R; Thakur B; Yadav R; Kumar M; Singh R; Dash NR; Sahni P; Chauhan SS
    Front Oncol; 2019; 9():1239. PubMed ID: 31824841
    [No Abstract]   [Full Text] [Related]  

  • 27. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.
    Haake SM; Li J; Bai Y; Kinose F; Fang B; Welsh EA; Zent R; Dhillon J; Pow-Sang JM; Chen YA; Koomen JM; Rathmell WK; Fishman M; Haura EB
    Clin Cancer Res; 2016 Nov; 22(22):5605-5616. PubMed ID: 27220961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor II receptor-mediated intracellular retention of cathepsin B is essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus.
    Rose PP; Bogyo M; Moses AV; Früh K
    J Virol; 2007 Aug; 81(15):8050-62. PubMed ID: 17507477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of tivozanib in advanced renal cell carcinoma therapy.
    Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic values of serum cathepsin B and D in patients with nasopharyngeal carcinoma.
    Tan G; Liu Q; Tang X; Kang T; Li Y; Lu J; Zhao X; Tang F
    BMC Cancer; 2016 Mar; 16():241. PubMed ID: 26995190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coprophagy Prevention Decreases the Reproductive Performance and Granulosa Cell Apoptosis
    Song G; Wang Y; Wang Y; Jiang Y; Sun S; Cai H; Sun G; Li M; Bionaz M; Xu H
    Front Physiol; 2022; 13():926795. PubMed ID: 35923240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Impact of sequential targeted therapy on progression-free survival in metastatic renal cell carcinoma].
    Si L; Bai X; Mao L; Wang X; Chi Z; Cui C; Sheng X; Tang B; Guo J
    Zhonghua Yi Xue Za Zhi; 2014 Sep; 94(33):2580-3. PubMed ID: 25511488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade.
    Ishibashi K; Haber T; Breuksch I; Gebhard S; Sugino T; Kubo H; Hata J; Koguchi T; Yabe M; Kataoka M; Ogawa S; Hiraki H; Yanagida T; Haga N; Thüroff JW; Prawitt D; Brenner W; Kojima Y
    Oncotarget; 2017 Aug; 8(33):55230-55245. PubMed ID: 28903416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
    Tannir NM; Schwab G; Grünwald V
    Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy.
    Buti S; Leonetti A; Dallatomasina A; Bersanelli M
    Core Evid; 2016; 11():23-36. PubMed ID: 27621699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells.
    Bronger H; Karge A; Dreyer T; Zech D; Kraeft S; Avril S; Kiechle M; Schmitt M
    Oncol Lett; 2017 Jun; 13(6):4224-4230. PubMed ID: 28599423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.